Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor δ

Pharmacogenetics and Genomics

Volumn 16, Issue 1, 2006, Pages 43-50

  Siezen, Christine L E ^a,b   Tijhuis, Mariken J ^c   Kram, Nicolien R ^a   Van Soest, Eva M ^c   De Jong, Dirk J ^d   Fodde, Riccardo ^b   Van Kranen, Henk J ^a   Kampman, Ellen ^c  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aspirin; Colorectal adenomas; Cyclooxygenase; Haplotypes; NSAIDs; PPAR; PTGS; SNP

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA;

ALLELE; ARTICLE; CANCER RISK; COLORECTAL ADENOMA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; ENDOSCOPY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; NETHERLANDS; PRIORITY JOURNAL; PROPHYLAXIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS;

EID: 29144526136     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fpc.0000182778.03180.f3     Document Type: Article

References (31)

1. Stewart SL, King JB, Thompson TD, Friedman C, Wingo PA. Cancer mortality surveillance - United States, 1990-2000. MMWR Surveill Summ 2004; 53:1-108.
2. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94:252-266.
3. Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol 2004; 31:12-21.
4. Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61:1733-1740.
5. Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003; 63:586-592.
6. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946-1952.
7. Kitamura T, Kawamori T, Uchiya N, Itoh M, Noda T, Matsuura M, et al. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis 2002; 23:1463-1466.
8. Clevers H. At the crossroads of inflammation and cancer. Cell 2004; 118:671-674.
9. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99:335-345.
10. Nixon JB, Kamitani H, Baek SJ, Eling TE. Evaluation of eicosanoids and NSAIDs as PPARgamma ligands in colorectal carcinoma cells. Prostaglandins Leukot Essent Fatty Acids 2003; 68:323-330.
11. Babbar N, Ignatenko NA, Casero RA Jr, Gerner EW. Cyclooxygenase- independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem 2003; 278:47762-47775.
12. Wick M, Hurteau G, Dessev C, Chan D, Geraci MW, Winn RA, et al. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 2002; 62:1207-1214.
13. Tiemersma EW, Wark PA, Ocke MC, Bunschoten A, Otten MH, Kok FJ, et al. Alcohol consumption alcohol dehydrogenase 3 polymorphism and colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2003; 12:419-425.
14. van den Donk M, Buijsse B, van den Berg SW, Ocke MC, Harryvan JL, Nagengast FM, et al. Dietary intake of folate and riboflavin, MTHFR C677T genotype and colorectal adenoma risk: a Dutch case-control study. Cancer Epidemiol Biomarkers Prev 2005; 14:1562-1566.
15. Ocke MC, Bueno-de-Mesquita HB, Goddijn HE, Jansen A, Pols MA, van Staveren WA, et al. The Dutch EPIC food frequency questionnaire. I. Description of the questionnaire and relative validity and reproducibility for food groups. Int J Epidemiol 1997; 26 (Suppl 1):37S-48S.
16. Ocke MC, Bueno-de-Mesquita HB, Pols MA, Smit HA, van Staveren WA, Kromhout D. The Dutch EPIC food frequency questionnaire. II. Relative validity and reproducibility for nutrients. Int J Epidemiol 1997; 26 (Suppl 1):49-58.
17. Ulrich CM, Bigler J, Sibert J, Greene EA, Sparks R, Carlson CS, et al. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum Mutat 2002; 20:409-410.
18. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, et al. PTGS2 (COX-2)-765G
19. Biotage. Pyrosequencing AB. [online] http://www.pyrosequencing.com. Accessed 8.9.2004.
20. Hoebee B, Bont L, Rietveld E, van Oosten M, Hodemaekers HM, Nagelkerke NJ, et al. Influence of promoter variants of interleukin-10, interleukin-9, and tumor necrosis factor-alpha genes on respiratory syncytial virus bronchiolitis. J Infect Dis 2004; 189:239-247.
21. Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, Kampman E. Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis 2005; 26:449-457.
22. Fred Hutchinson Cancer Research Center. Hplus. [online] http://qge.fhcrc.org/hplus. Accessed 26.10.2004.
23. Zhao LP, Li SS, Khalid N. A method for the assessment of disease associations with single-nucleotide polymorphism haplotypes and environmental variables in case-control studies. Am J Hum Genet 2003; 72:1231-1250.
24. Tiemersma EW, Bunschoten A, Kok FJ, Glatt H, de Boer SY, Kampman E. Effect of SULT1A1 and NAT2 genetic polymorphism on the association between cigarette smoking and colorectal adenomas. Int J Cancer 2004; 108:97-103.
25. Kojo H, Fukagawa M, Tajima K, Suzuki A, Fujimura T, Aramori I, et al. Evaluation of human peroxisome proliferator-activated receptor (PPAR) subtype selectivity of a variety of anti-inflammatory drugs based on a novel assay for PPAR delta(beta). J Pharmacol Sci 2003; 93:347-355.
26. NCBI. dbSNP. [online] http://www.ncbi.nlm.nih.gov/SNP/. Accessed 18.4.2005.
27. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000; 342:1960-1968.
28. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 2004; 4:61-70.
29. Computational Biology Research Center. TFSEARCH. [online] http://www.cbrc.jp/research/db/TFSEARCH.html. Accessed 6.12.2004.
30. Ulrich CM, Bigler J, Sparks R, Whitton J, Sibert JG, Goode EL, et al. Polymorphisms in PTGS1 (=COX-1) and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2004; 13:889-893.
31. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal antiinflammatory agents differ in their ability to suppress NF-kappaB, activation inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004; 23:9247-9258.